Methotrexate News and Research

RSS
Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.

Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
Researchers explain possibility of using biomarkers in children with JIA to predict status of disease

Researchers explain possibility of using biomarkers in children with JIA to predict status of disease

Obese patients with rheumatoid arthritis have higher disease activity scores

Obese patients with rheumatoid arthritis have higher disease activity scores

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma announces launch of OTREXUP to Dermatologists

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Medac Pharma announces FDA acceptance of New Drug Application for MPI-2505

Medac Pharma announces FDA acceptance of New Drug Application for MPI-2505

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Death rates two times higher in postmenopausal women with anti-CCP and RA antibodies

Death rates two times higher in postmenopausal women with anti-CCP and RA antibodies

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients